Revenue growth of 6%, with strength across all three segments
As reported, earnings increased 8% to $0.52 per diluted share
Board of Directors increases quarterly dividend by two cents to $0.19 per share
Mentor, Ohio (August 2, 2012) - STERIS Corporation (NYSE: STE) today announced financial results for its fiscal 2013 first quarter ended June 30, 2012. As reported, fiscal 2013 first quarter revenue increased 6% to $337.0 million compared with $318.6 million in the first quarter of fiscal 2012, with revenue growth across all three business segments.
Fiscal 2013 first quarter operating income was $48.3 million compared with operating income of $46.9 million in the first quarter of fiscal 2012. Fiscal 2013 first quarter net income was $30.4 million, or $0.52 per diluted share, compared with net income of $28.7 million, or $0.48 per diluted share in the first quarter of fiscal 2012. Adjusted earnings per share increased to $0.53 compared with $0.50 per diluted share in the first quarter of fiscal 2012. Adjusted earnings exclude the amortization of purchased intangible assets, acquisition related transaction and integration costs, and certain other items identified in the attached table to provide meaningful comparative analysis.
"We are pleased to have a strong start to fiscal 2013, with growth across all businesses and performance better than our expectations," said Walt Rosebrough, President and Chief Executive Officer of STERIS. "Our business outside of SYSTEM 1 continues to deliver robust performance, which has allowed us to more than offset expected S20 sterilant sales declines, and to grow earnings compared with last year. Our expectations for earnings per diluted share for the full year are in-line with our prior GAAP outlook of $2.00 to $2.20. On an adjusted basis, earnings per diluted share are anticipated to be in the range of $2.15 to $2.35 for the full year, including five cents of accretion from the proposed US Endoscopy acquisition, excluding certain costs."
Segment Results Healthcare revenue in the quarter was $229.5 million, an increase of 3% compared with $223.2 million in the first quarter of fiscal 2012. Revenue growth was driven by 7% growth in capital equipment and a 3% increase in service revenue. Consumable revenue declined 5% due to continued declines in S20 sterilant volume. Operating income was $22.7 million compared with operating income of $26.3 million in last year's first quarter. The decline in operating income year-over-year was due to a reduction in gross margin, increased spending on research and development, and higher SYSTEM 1E product reliability expenses.
Life Sciences first quarter revenue increased 14% to $60.5 million compared with $52.9 million in the first quarter of fiscal 2012. Revenue growth was driven by a 36% increase in capital equipment, 4% growth in consumables and 3% growth in service revenue. Life Sciences operating income was $11.9 million compared with $9.5 million in the prior year first quarter. The increase in operating income was driven by higher volumes and improved operating leverage.
Fiscal 2013 first quarter revenue for Isomedix Services was $46.1 million compared with $42.0 million in the same period last year, an increase of 10%. Revenue benefitted from increased volumes from core medical device Customers as well as the recent acquisition of Biotest, which added 400 basis points to growth. Operating income was $15.6 million in the quarter compared with $13.0 million in the first quarter of last year.
Cash Flow Net cash provided by operations for the first quarter of fiscal 2013 was $61.3 million, compared with $12.0 million last year. Free cash flow (see note 1) for the first quarter of fiscal 2013 was $45.7 million, compared with negative $3.6 million in the prior year. The improvement in free cash flow is due to improvements in working capital management, specifically the anticipated reduction of over $28 million in SYSTEM 1E related inventory and lower days sales outstanding.
Dividend Announcement The Company also announced today that STERIS's Board of Directors has authorized a two cent increase in its quarterly dividend to $0.19 per common share, representing the seventh consecutive year of double digit percentage increases in the dividend. The dividend is payable September 20, 2012 to shareholders of record at the close of business on August 23, 2012.
O utlook STERIS announced the proposed acquisition of US Endoscopy on July 17, 2012. Reflecting the impact of that acquisition, the Company now expects revenue growth for fiscal 2013 to be in the range of 3-4%, compared with previous expectations of flat revenue performance. Similarly, Healthcare segment revenue is expected to grow low-single digits, compared with previous expectations of a decline in revenue of low-single digits. The revenue outlook for Life Sciences and Isomedix is unchanged.
The Company is maintaining its outlook for earnings per diluted share on a U.S. GAAP basis in the range of $2.00 to $2.20 for fiscal 2013, which includes approximately five cents of dilution from the proposed US Endoscopy acquisition.
Going forward, STERIS will provide U.S. GAAP earnings as well as adjusted earnings per share. Adjusted earnings will exclude the amortization of purchased intangible assets, acquisition related transaction and integration costs, and certain other items to provide meaningful comparative analysis. The Company has provided adjusted financial results for fiscal 2012 in order to provide meaningful year-over-year comparisons. Adjusted earnings per diluted share for fiscal 2013 are anticipated to be in the range of $2.15 to $2.35, including accretion of approximately five cents per share from the proposed acquisition of US Endoscopy. Please see the attached financial tables for a complete reconciliation of these non-GAAP numbers to the nearest GAAP information.
The Company's outlook for fiscal 2013 reflects certain key assumptions, some of which are listed below:
The Company has assumed the average forward exchange rates for the U.S. dollar and key international currencies as of June 29, 2012.
The Company has assumed a modest increase in raw material costs.
Excludes restructuring expenses from the Company's ongoing efficiency efforts.
Excludes the impact of the Medical Device Excise Tax; potential earning per share impact could be in the range of $0.02 to $0.04.
EBIT as a percent of revenue is anticipated to be approximately 14% on a U.S. GAAP basis including US Endoscopy.
The effective tax rate is anticipated to be approximately 35%.
For the full fiscal year 2013, free cash flow (see note 1) is now anticipated to be approximately $130 million excluding the SYSTEM 1 Rebate Program and class action settlement, or $90 million including those items.
Conference Call
In conjunction with this release, STERIS Corporation management will host a conference call today at 10:00 a.m. Eastern time. The conference call can be heard live over the Internet at www.steris-ir.com or via phone by dialing 1-800-369-8428 in the United States and Canada, and 1-773-799-3378 internationally, then referencing the password "STERIS".
For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m. Eastern time on August 2, 2012, either over the Internet at www.steris-ir.com or via phone by calling 1-866-350-7007 in the United States and Canada, and 1-203-369-0047 internationally.
About STERIS The mission of STERIS Corporation is to provide a healthier today and safer tomorrow through knowledgeable people and innovative infection prevention, decontamination and health science technologies, products and services. The Company has approximately 5,000 dedicated employees around the world working together to supply a broad array of solutions by offering a combination of equipment, consumables and services to healthcare, pharmaceutical, industrial and government Customers. The Company is listed on the New York Stock Exchange under the symbol STE. For more information, visit www.steris.com.
(1) Free cash flow is a non-GAAP number used by the Company as a measure to gauge its ability to fund future principal debt repayments, growth outside of core operations, repurchase common shares, and pay cash dividends. Free cash flow is defined as net cash flows from operating activities less purchases of property, plant, equipment and intangibles, net, plus proceeds from the sale of property, plant, equipment and intangibles. STERIS's calculation of free cash flow may vary from other companies. Please see the attached financial tables for a complete reconciliation of these non-GAAP numbers to the nearest GAAP information.
# # #
This press release and the referenced conference call may contain statements concerning certain trends, expectations, forecasts, estimates, or other forward-looking information affecting or relating to the Company or its industry, products or activities that are intended to qualify for the protections afforded "forward-looking statements" under the Private Securities Litigation Reform Act of 1995 and other laws and regulations. Forward-looking statements speak only as to the date of this press release, and may be identified by the use of forward-looking terms such as "may," "will," "expects," "believes," "anticipates," "plans," "estimates," "projects," "targets," "forecasts," "outlook," "impact," "potential," "confidence," "improve," "optimistic," "deliver," "comfortable," "trend", and "seeks," or the negative of such terms or other variations on such terms or comparable terminology. Many important factors could cause actual results to differ materially from those in the forward-looking statements including, without limitation, disruption of production or supplies, changes in market conditions, political events, pending or future claims or litigation, competitive factors, technology advances, actions of regulatory agencies, and changes in laws, government regulations, labeling or product approvals or the application or interpretation thereof. Other risk factors are described herein and in the Company's Form 10-K and other securities filings. Many of these important factors are outside STERIS's control. No assurances can be provided as to any result or the timing of any outcome regarding matters described in this press release, the referenced conference call or otherwise with respect to any regulatory action, administrative proceedings, government investigations, litigation, warning letters, consent decree, rebate program, transition, cost reductions, business strategies, earnings or revenue trends or future financial results (including without limitation the settlement of the SYSTEM 1 class action litigation and the regulatory matters related to SYSTEM 1E or its accessories). References to products, the consent decree, the transition or rebate program, or the class action settlement, are summaries only and should not be considered the specific terms of the decree, settlement, program or product clearance or literature. Unless legally required, the Company does not undertake to update or revise any forward-looking statements even if events make clear that any projected results, express or implied, will not be realized. Other potential risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, (a) the potential for increased pressure on pricing or costs that leads to erosion of profit margins, (b) the possibility that market demand will not develop for new technologies, products or applications or the Company's rebate program, transition plan or other business initiatives will take longer, cost more or produce lower benefits than anticipated, (c) the possibility that application of or compliance with laws, court rulings, certifications, regulations, regulatory actions, including without limitation those relating to FDA warning notices or letters, government investigations, the April 20, 2010 consent decree and related transition plan and rebate program, the SYSTEM 1E device, the outcome of any pending FDA requests, inspections or submissions, or other requirements or standards may delay, limit or prevent new product introductions, affect the production and marketing of existing products or services or otherwise affect Company performance, results, prospects or value, (d) the potential of international unrest, economic downturn or effects of currencies, tax assessments, adjustments, or anticipated rates, raw material costs or availability, benefit or retirement plan costs, or other regulatory compliance costs, (e) the possibility of reduced demand, or reductions in the rate of growth in demand, for the Company's products and services, (f) the possibility that anticipated growth, cost savings, rebate assumptions, new product acceptance, performance or approvals, including without limitation SYSTEM 1E and accessories thereto, or other results may not be achieved, or that transition, labor, competition, timing, execution, regulatory, governmental, or other issues or risks associated with our business, industry or initiatives including, without limitation, the consent decree, rebate program, and the transition from the SYSTEM 1 processing system and adjustments to related reserves, or those matters described in our Form 10-K for the year ended March 31, 2012 and other securities filings, may adversely impact company performance, results, prospects or value, (g) the possibility that anticipated benefits and results of the US Endoscopy transaction will not be realized or will be other than anticipated, (h) the effect of the contraction in credit availability, as well as the ability of our Customers and suppliers to adequately access the credit markets when needed, and (i) those risks described in our securities filings including our Annual Report on Form 10-K for the year ended March 31, 2012, and other securities filings.
Contact: Julie Winter, Director, Investor Relations at 440-392-7245.
STERIS Q1 FY13 Financials
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Steris Corporation via Thomson Reuters ONE
HUG#1631299